chr14-87950723-C-T
Variant summary
Our verdict is Likely pathogenic. Variant got 9 ACMG points: 9P and 0B. PM1PM2PM5PP3_ModeratePP5
The NM_000153.4(GALC):c.1187G>A(p.Arg396Gln) variant causes a missense change. The variant allele was found at a frequency of 0.000005 in 1,601,430 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R396L) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000153.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 9 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GALC | NM_000153.4 | c.1187G>A | p.Arg396Gln | missense_variant | 11/17 | ENST00000261304.7 | NP_000144.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GALC | ENST00000261304.7 | c.1187G>A | p.Arg396Gln | missense_variant | 11/17 | 1 | NM_000153.4 | ENSP00000261304 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000137 AC: 2AN: 146096Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000403 AC: 1AN: 248256Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 134778
GnomAD4 exome AF: 0.00000412 AC: 6AN: 1455334Hom.: 0 Cov.: 28 AF XY: 0.00000276 AC XY: 2AN XY: 724208
GnomAD4 genome AF: 0.0000137 AC: 2AN: 146096Hom.: 0 Cov.: 32 AF XY: 0.0000283 AC XY: 2AN XY: 70762
ClinVar
Submissions by phenotype
Galactosylceramide beta-galactosidase deficiency Pathogenic:1Uncertain:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 14, 2023 | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 396 of the GALC protein (p.Arg396Gln). This variant is present in population databases (no rsID available, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with GALC-related conditions. ClinVar contains an entry for this variant (Variation ID: 556049). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt GALC protein function with a positive predictive value of 95%. This variant disrupts the p.Arg396 amino acid residue in GALC. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 3362311, 9338580, 21876145, 24297913, 26795590, 27638592, 27638593). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Jan 09, 2018 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 29, 2023 | Variant summary: GALC c.1187G>A (p.Arg396Gln) results in a conservative amino acid change located in the Glycosyl hydrolase family 59, central domain (IPR035394) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4e-06 in 248256 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.1187G>A has been reported in the literature in at least one compound heterozygous individual affected with Krabbe Disease (e.g. Wang_2016). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 27779215). A different variant located at the same codon (c.1186C>T, p.Arg396Trp) has been classified as pathogenic in association with Krabbe Disease, supporting a critical relevance of this residue to GALC protein function. Two submitters have cited clinical-significance assessments for this variant to ClinVar after 2014. One submitter classified the variant as likely pathogenic, and one submitter classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at